Search

Boehringer Ingelheim opens Health Management Centre in China

Boehringer Ingelheim opens Health Management Centre in China The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring tools The centre further strengthens the company’s ability to provide services along the f

Launch of Frontline flagship store on Tmall

Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.

Streetvet: Free veterinary care

Learn more about StreetVet free veterinarian care for companion animals of the homeless

U.S. FDA grants priority review for spesolimab in GPP

U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis

Phase II trials for patients with bronchiectasis

Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.

Generalized pustular psoriasis: The Impact Beyond The Skin

An article on how the symptoms of generalized pustular psoriasis (GPP) are more than just physical, affecting both mental and emotional health

Pride Month 2023: Why belonging matters – to all of us

LGBTIQ+ community members and their allies share how we can create a welcoming and inclusive culture where everyone feels heard, accepted and appreciated.

Targeting Tumor Stroma

Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients

Heart Diseases in humans and animals

Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well.

Mental health: a $1 trillion burden demanding policy action

Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.

On two wheels for more animal health

Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.

Groundbeaking of vaccine production center in France

Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health

Winners of BVDzero Scholarship Programme

Boehringer Ingelheim announces winners of BVDzero Scholarship Programme

Official partner to Cat Care for Life

Boehringer Ingelheim announces its new partnership with the CatCareforLife program.

Stem cell therapy for tendon and ligament injuries in horses

A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.

H5N1: Bird flu again. What’s different now?

H5N1: how is avian influenza now? The virus known for affecting wild & domestic birds has been detected in dairy cows in the US. What you need to know.

Mareks Disease Poultry Chicken

Five things you need to know to keep poultry free from outcomes of one of the most common virus affecting the animals’ immune systems.

Interview Dr Mehdi Shahidi

Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim

Bluetongue disease

The bluetongue virus is a viral disease that affects ruminants' health. It doesn't affect humans, but it is a threat to animals.

Scam alert

A recruitment scam involving Boehringer Ingelheim is circulating.

Veronika Kohlbrenner

Veronika Kohlbrenner, Patient Safety Physician in Therapeutic Area Inflammation, tells us how she is able to work across different levels of the drug development process.

Phase 1 start of treatment for Geographic Atrophy patients

Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)

India: Many positive developments for the population

A conversation with interim country manager Sandip Agrawal about a young and growing country

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor

Boehringer Ingelheim announces collaboration with MabGenesis

Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers